Q1 2025 13F Holders as of 3/31/2025
-
Type / Class
-
Equity / COMMON STOCK
-
Shares outstanding
-
112M
-
Number of holders
-
365
-
Total 13F shares, excl. options
-
76.2M
-
Shares change
-
-6.31M
-
Total reported value, excl. options
-
$1.84B
-
Value change
-
-$233M
-
Put/Call ratio
-
0.41
-
Number of buys
-
219
-
Number of sells
-
-197
-
Price
-
$24.15
Significant Holders of Viking Therapeutics, Inc. - COMMON STOCK (VKTX) as of Q1 2025
509 filings reported holding VKTX - Viking Therapeutics, Inc. - COMMON STOCK as of Q1 2025.
Viking Therapeutics, Inc. - COMMON STOCK (VKTX) has 365 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 76.2M shares
of 112M outstanding shares and own 67.85% of the company stock.
Largest 10 shareholders include FMR LLC (11.2M shares), VANGUARD GROUP INC (10.2M shares), BlackRock, Inc. (5.98M shares), STATE STREET CORP (4.06M shares), JPMORGAN CHASE & CO (3.13M shares), MORGAN STANLEY (3.12M shares), GEODE CAPITAL MANAGEMENT, LLC (1.98M shares), Pictet Asset Management Holding SA (1.92M shares), SUSQUEHANNA INTERNATIONAL GROUP, LLP (1.68M shares), and CITADEL ADVISORS LLC (1.65M shares).
This table shows the top 365 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.